This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (January 2009)

Insulin crystals.

Biotechnology (sometimes shortened to "biotech") is a field of applied biology that involves the use of living organisms and bioprocesses in engineering, technology, medicine and other fields requiring bioproducts. Biotechnology also utilizes these products for manufacturing purpose. Modern use of similar terms includes genetic engineering as well as cell and tissue culture technologies. The concept encompasses a wide range of procedures (and history) for modifying living organisms according to human purposes — going back to domestication of animals, cultivation of plants, and "improvements" to these through breeding programs that employ artificial selection and hybridization. By comparison to biotechnology, bioengineering is generally thought of as a related field with its emphasis more on higher systems approaches (not necessarily altering or using biological materials directly) for interfacing with and utilizing living things. The United Nations Convention on Biological Diversity defines biotechnology as:^[1]

"Any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use."

In other terms: "Application of scientific and technical advances in life science to develop commercial products" is biotechnology. Biotechnology draws on the pure biological sciences (genetics, microbiology, animal cell culture, molecular biology, biochemistry, embryology, cell biology) and in many instances it is also dependent on knowledge and methods from outside the sphere of biology (chemical engineering, bioprocess engineering, information technology, biorobotics). Conversely, modern biological sciences (including even concepts such as molecular ecology) are intimately entwined and dependent on the methods developed through biotechnology and what is commonly thought of as the life sciences industry.

History[link]

Brewing was an early application of biotechnology

Biotechnology is not limited to medical/health applications (unlike Biomedical Engineering, which includes much biotechnology). Although not normally thought of as biotechnology, agriculture clearly fits the broad definition of "using a biotechnological system to make products" such that the cultivation of plants may be viewed as the earliest biotechnological enterprise. Agriculture has been theorized to have become the dominant way of producing food since the Neolithic Revolution. The processes and methods of agriculture have been refined by other mechanical and biological sciences since its inception. Through early biotechnology, farmers were able to select the best suited crops, having the highest yields, to produce enough food to support a growing population. Other uses of biotechnology were required as the crops and fields became increasingly large and difficult to maintain. Specific organisms and organism by-products were used to fertilize, restore nitrogen, and control pests. Throughout the use of agriculture, farmers have inadvertently altered the genetics of their crops through introducing them to new environments and breeding them with other plants—one of the first forms of biotechnology. Cultures such as those in Mesopotamia, Egypt, and India developed the process of brewing beer. It is still done by the same basic method of using malted grains (containing enzymes) to convert starch from grains into sugar and then adding specific yeasts to produce beer. In this process the carbohydrates in the grains were broken down into alcohols such as ethanol. Later other cultures produced the process of lactic acid fermentation which allowed the fermentation and preservation of other forms of food. Fermentation was also used in this time period to produce leavened bread. Although the process of fermentation was not fully understood until Pasteur's work in 1857, it is still the first use of biotechnology to convert a food source into another form.

For thousands of years, humans have used selective breeding to improve production of crops and livestock to use them for food. In selective breeding, organisms with desirable characteristics are mated to produce offspring with the same characteristics. For example, this technique was used with corn to produce the largest and sweetest crops.^[2]

In the early twentieth century scientists gained a greater understanding of microbiology and explored ways of manufacturing specific products. In 1917,. Chaim Weizmann first used a pure microbiological culture in an industrial process, that of manufacturing corn starch using Clostridium acetobutylicum, to produce acetone, which the United Kingdom desperately needed to manufacture explosives during World War I.^[3]

Biotechnology has also led to the development of antibiotics. In 1928, Alexander Fleming discovered the mold Penicillium. His work led to the purification of the antibiotic by Howard Florey, Ernst Boris Chain and Norman Heatley penicillin. In 1940, penicillin became available for medicinal use to treat bacterial infections in humans.^[2]

The field of modern biotechnology is thought to have largely begun on June 16, 1980, when the United States Supreme Court ruled that a genetically modified microorganism could be patented in the case of Diamond v. Chakrabarty.^[4] Indian-born Ananda Chakrabarty, working for General Electric, had developed a bacterium (derived from the Pseudomonas genus) capable of breaking down crude oil, which he proposed to use in treating oil spills.

Revenue in the industry is expected to grow by 12.9% in 2008. Another factor influencing the biotechnology sector's success is improved intellectual property rights legislation—and enforcement—worldwide, as well as strengthened demand for medical and pharmaceutical products to cope with an ageing, and ailing, U.S. population.^[5]

Rising demand for biofuels is expected to be good news for the biotechnology sector, with the Department of Energy estimating ethanol usage could reduce U.S. petroleum-derived fuel consumption by up to 30% by 2030. The biotechnology sector has allowed the U.S. farming industry to rapidly increase its supply of corn and soybeans—the main inputs into biofuels—by developing genetically modified seeds which are resistant to pests and drought. By boosting farm productivity, biotechnology plays a crucial role in ensuring that biofuel production targets are met.^[6]

Applications[link]

A rose plant that began as cells grown in a tissue culture

Biotechnology has applications in four major industrial areas, including health care (medical), crop production and agriculture, non food (industrial) uses of crops and other products (e.g. biodegradable plastics, vegetable oil, biofuels), and environmental uses.

For example, one application of biotechnology is the directed use of organisms for the manufacture of organic products (examples include beer and milk products). Another example is using naturally present bacteria by the mining industry in bioleaching. Biotechnology is also used to recycle, treat waste, cleanup sites contaminated by industrial activities (bioremediation), and also to produce biological weapons.

A series of derived terms have been coined to identify several branches of biotechnology; for example:

• Bioinformatics is an interdisciplinary field which addresses biological problems using computational techniques, and makes the rapid organization and analysis of biological data possible. The field may also be referred to as computational biology, and can be defined as, "conceptualizing biology in terms of molecules and then applying informatics techniques to understand and organize the information associated with these molecules, on a large scale."^[7] Bioinformatics plays a key role in various areas, such as functional genomics, structural genomics, and proteomics, and forms a key component in the biotechnology and pharmaceutical sector.
• Blue biotechnology is a term that has been used to describe the marine and aquatic applications of biotechnology, but its use is relatively rare.
• Green biotechnology is biotechnology applied to agricultural processes. An example would be the selection and domestication of plants via micropropagation. Another example is the designing of transgenic plants to grow under specific environments in the presence (or absence) of chemicals. One hope is that green biotechnology might produce more environmentally friendly solutions than traditional industrial agriculture. An example of this is the engineering of a plant to express a pesticide, thereby ending the need of external application of pesticides. An example of this would be Bt corn. Whether or not green biotechnology products such as this are ultimately more environmentally friendly is a topic of considerable debate.
• Red biotechnology is applied to medical processes. Some examples are the designing of organisms to produce antibiotics, and the engineering of genetic cures through genetic manipulation.
• White biotechnology, also known as industrial biotechnology, is biotechnology applied to industrial processes. An example is the designing of an organism to produce a useful chemical. Another example is the using of enzymes as industrial catalysts to either produce valuable chemicals or destroy hazardous/polluting chemicals. White biotechnology tends to consume less in resources than traditional processes used to produce industrial goods.^{[citation needed]}

The investment and economic output of all of these types of applied biotechnologies is termed as bioeconomy.

Medicine[link]

In medicine, modern biotechnology finds promising applications in such areas as

• drug production
• pharmacogenomics
• gene therapy
• genetic testing (or genetic screening): techniques in molecular biology detect genetic diseases. To test the developing fetus for Down syndrome, Amniocentesis and chorionic villus sampling can be used.^[2]

Pharmacogenomics[link]

DNA microarray chip – some can do as many as a million blood tests at once

Pharmacogenomics is the study of how the genetic inheritance of an individual affects his/her body's response to drugs. It is a portmanteau derived from the words "pharmacology" and "genomics". It is hence the study of the relationship between pharmaceuticals and genetics. The vision of pharmacogenomics is to be able to design and produce drugs that are adapted to each person's genetic makeup.^[8]

Pharmacogenomics results in the following benefits:^[8]

1. Development of tailor-made medicines. Using pharmacogenomics, pharmaceutical companies can create drugs based on the proteins, enzymes and RNA molecules that are associated with specific genes and diseases. These tailor-made drugs promise not only to maximize therapeutic effects but also to decrease damage to nearby healthy cells.
2. More accurate methods of determining appropriate drug dosages. Knowing a patient's genetics will enable doctors to determine how well his/ her body can process and metabolize a medicine. This will maximize the value of the medicine and decrease the likelihood of overdose.
3. Improvements in the drug discovery and approval process. The discovery of potential therapies will be made easier using genome targets. Genes have been associated with numerous diseases and disorders. With modern biotechnology, these genes can be used as targets for the development of effective new therapies, which could significantly shorten the drug discovery process.
4. Better vaccines. Safer vaccines can be designed and produced by organisms transformed by means of genetic engineering. These vaccines will elicit the immune response without the attendant risks of infection. They will be inexpensive, stable, easy to store, and capable of being engineered to carry several strains of pathogen at once.

Pharmaceutical products[link]

Computer-generated image of insulin hexamers highlighting the threefold symmetry, the zinc ions holding it together, and the histidine residues involved in zinc binding.

Most traditional pharmaceutical drugs are relatively simple molecules that have been found primarily through trial and error to treat the symptoms of a disease or illness.^{[citation needed]} Biopharmaceuticals are large biological molecules such as proteins and these usually target the underlying mechanisms and pathways of a malady (but not always, as is the case with using insulin to treat type 1 diabetes mellitus, as that treatment merely addresses the symptoms of the disease, not the underlying cause which is autoimmunity); it is a relatively young industry. They can deal with targets in humans that may not be accessible with traditional medicines. A patient typically is dosed with a small molecule via a tablet while a large molecule is typically injected.

Small molecules are manufactured by chemistry but larger molecules are created by living cells such as those found in the human body: for example, bacteria cells, yeast cells, animal or plant cells.

Modern biotechnology is often associated with the use of genetically altered microorganisms such as E. coli or yeast for the production of substances like synthetic insulin or antibiotics. It can also refer to transgenic animals or transgenic plants, such as Bt corn. Genetically altered mammalian cells, such as Chinese Hamster Ovary cells (CHO), are also used to manufacture certain pharmaceuticals. Another promising new biotechnology application is the development of plant-made pharmaceuticals.

Biotechnology is also commonly associated with landmark breakthroughs in new medical therapies to treat hepatitis B, hepatitis C, cancers, arthritis, haemophilia, bone fractures, multiple sclerosis, and cardiovascular disorders. The biotechnology industry has also been instrumental in developing molecular diagnostic devices that can be used to define the target patient population for a given biopharmaceutical. Herceptin, for example, was the first drug approved for use with a matching diagnostic test and is used to treat breast cancer in women whose cancer cells express the protein HER2.

Modern biotechnology can be used to manufacture existing medicines relatively easily and cheaply. The first genetically engineered products were medicines designed to treat human diseases. To cite one example, in 1978 Genentech developed synthetic humanized insulin by joining its gene with a plasmid vector inserted into the bacterium Escherichia coli. Insulin, widely used for the treatment of diabetes, was previously extracted from the pancreas of abattoir animals (cattle and/or pigs). The resulting genetically engineered bacterium enabled the production of vast quantities of synthetic human insulin at relatively low cost.^[9] According to a 2003 study undertaken by the International Diabetes Federation (IDF) on the access to and availability of insulin in its member countries, synthetic 'human' insulin is considerably more expensive in most countries where both synthetic 'human' and animal insulin are commercially available: e.g. within European countries the average price of synthetic 'human' insulin was twice as high as the price of pork insulin.^[10] Yet in its position statement, the IDF writes that "there is no overwhelming evidence to prefer one species of insulin over another" and "[modern, highly purified] animal insulins remain a perfectly acceptable alternative.^[11]

Modern biotechnology has evolved, making it possible to produce more easily and relatively cheaply human growth hormone, clotting factors for hemophiliacs, fertility drugs, erythropoietin and other drugs.^[12] Most drugs today are based on about 500 molecular targets. Genomic knowledge of the genes involved in diseases, disease pathways, and drug-response sites are expected to lead to the discovery of thousands more new targets.^[12]

Genetic testing[link]

Gel electrophoresis

Genetic testing involves the direct examination of the DNA molecule itself. A scientist scans a patient's DNA sample for mutated sequences.

There are two major types of gene tests. In the first type, a researcher may design short pieces of DNA ("probes") whose sequences are complementary to the mutated sequences. These probes will seek their complement among the base pairs of an individual's genome. If the mutated sequence is present in the patient's genome, the probe will bind to it and flag the mutation. In the second type, a researcher may conduct the gene test by comparing the sequence of DNA bases in a patient's gene to disease in healthy individuals or their progeny.

Genetic testing is now used for:

• Carrier screening, or the identification of unaffected individuals who carry one copy of a gene for a disease that requires two copies for the disease to manifest;
• Confirmational diagnosis of symptomatic individuals;
• Determining sex;
• Forensic/identity testing;
• Newborn screening;
• Prenatal diagnostic screening;
• Presymptomatic testing for estimating the risk of developing adult-onset cancers;
• Presymptomatic testing for predicting adult-onset disorders.

Some genetic tests are already available, although most of them are used in developed countries. The tests currently available can detect mutations associated with rare genetic disorders like cystic fibrosis, sickle cell anemia, and Huntington's disease. Recently, tests have been developed to detect mutation for a handful of more complex conditions such as breast, ovarian, and colon cancers. However, gene tests may not detect every mutation associated with a particular condition because many are as yet undiscovered.

Controversial questions[link]

The bacterium Escherichia coli is routinely genetically engineered.

The absence of privacy and anti-discrimination legal protections in most countries can lead to discrimination in employment or insurance or other use of personal genetic information. This raises questions such as whether genetic privacy is different from medical privacy.^[13]

1. Reproductive issues. These include the use of genetic information in reproductive decision-making and the possibility of genetically altering reproductive cells that may be passed on to future generations. For example, germline therapy changes the genetic make-up of an individual's descendants. Thus, any error in technology or judgment may have far-reaching consequences (though the same can also happen through natural reproduction). Ethical issues like designed babies and human cloning have also given rise to controversies between and among scientists and bioethicists, especially in the light of past abuses with eugenics (see reductio ad hitlerum).
2. Clinical issues. These center on the capabilities and limitations of doctors and other health-service providers, people identified with genetic conditions, and the general public in dealing with genetic information.
3. Effects on social institutions. Genetic tests reveal information about individuals and their families. Thus, test results can affect the dynamics within social institutions, particularly the family.
4. Conceptual and philosophical implications regarding human responsibility, free will vis-à-vis genetic determinism, and the concepts of health and disease.

Gene therapy[link]

Gene therapy using an Adenovirus vector. A new gene is inserted into an adenovirus vector, which is used to introduce the modified DNA into a human cell. If the treatment is successful, the new gene will make a functional protein.

Gene therapy may be used for treating, or even curing, genetic and acquired diseases like cancer and AIDS by using normal genes to supplement or replace defective genes or to bolster a normal function such as immunity. It can be used to target somatic cells (i.e., those of the body) or gamete (i.e., egg and sperm) cells. In somatic gene therapy, the genome of the recipient is changed, but this change is not passed along to the next generation. In contrast, in germline gene therapy, the egg and sperm cells of the parents are changed for the purpose of passing on the changes to their offspring.

There are basically two ways of implementing a gene therapy treatment:

1. Ex vivo, which means "outside the body" – Cells from the patient's blood or bone marrow are removed and grown in the laboratory. They are then exposed to a virus carrying the desired gene. The virus enters the cells, and the desired gene becomes part of the DNA of the cells. The cells are allowed to grow in the laboratory before being returned to the patient by injection into a vein.
2. In vivo, which means "inside the body" – No cells are removed from the patient's body. Instead, vectors are used to deliver the desired gene to cells in the patient's body.

As of June 2001, more than 500 clinical gene-therapy trials involving about 3,500 patients have been identified worldwide. Around 78% of these are in the United States, with Europe having 18%. These trials focus on various types of cancer, although other multigenic diseases are being studied as well. Recently, two children born with severe combined immunodeficiency disorder ("SCID") were reported to have been cured after being given genetically engineered cells.

Gene therapy faces many obstacles before it can become a practical approach for treating disease.^[13] At least four of these obstacles are as follows:

1. Gene delivery tools. Genes are inserted into the body using gene carriers called vectors. The most common vectors now are viruses, which have evolved a way of encapsulating and delivering their genes to human cells in a pathogenic manner. Scientists manipulate the genome of the virus by removing the disease-causing genes and inserting the therapeutic genes. However, while viruses are effective, they can introduce problems like toxicity, immune and inflammatory responses, and gene control and targeting issues. In addition, in order for gene therapy to provide permanent therapeutic effects, the introduced gene needs to be integrated within the host cell's genome. Some viral vectors effect this in a random fashion, which can introduce other problems such as disruption of an endogenous host gene.
2. High costs. Since gene therapy is relatively new and at an experimental stage, it is an expensive treatment to undertake. This explains why current studies are focused on illnesses commonly found in developed countries, where more people can afford to pay for treatment. It may take decades before developing countries can take advantage of this technology.
3. Limited knowledge of the functions of genes. Scientists currently know the functions of only a few genes. Hence, gene therapy can address only some genes that cause a particular disease. Worse, it is not known exactly whether genes have more than one function, which creates uncertainty as to whether replacing such genes is indeed desirable.
4. Multigene disorders and effect of environment. Most genetic disorders involve more than one gene. Moreover, most diseases involve the interaction of several genes and the environment. For example, many people with cancer not only inherit the disease gene for the disorder, but may have also failed to inherit specific tumor suppressor genes. Diet, exercise, smoking and other environmental factors may have also contributed to their disease.

Human Genome Project[link]

DNA Replication image from the Human Genome Project (HGP)

The Human Genome Project is an initiative of the U.S. Department of Energy ("DOE") and the National Institutes of Health ("NIH") that aims to generate a high-quality reference sequence for the entire human genome and identify all the human genes.

The DOE and its predecessor agencies were assigned by the U.S. Congress to develop new energy resources and technologies and to pursue a deeper understanding of potential health and environmental risks posed by their production and use. In 1986, the DOE announced its Human Genome Initiative. Shortly thereafter, the DOE and National Institutes of Health developed a plan for a joint Human Genome Project ("HGP"), which officially began in 1990.

The HGP was originally planned to last 15 years. However, rapid technological advances and worldwide participation accelerated the completion date to 2003 (making it a 13 year project). Already it has enabled gene hunters to pinpoint genes associated with more than 30 disorders.^[14]

Cloning[link]

Cloning involves the removal of the nucleus from one cell and its placement in an unfertilized egg cell whose nucleus has either been deactivated or removed.

There are two types of cloning:

1. Reproductive cloning. After a few divisions, the egg cell is placed into a uterus where it is allowed to develop into a fetus that is genetically identical to the donor of the original nucleus.
2. Therapeutic cloning.^[15] The egg is placed into a Petri dish where it develops into embryonic stem cells, which have shown potentials for treating several ailments.^[16]

In February 1997, cloning became the focus of media attention when Ian Wilmut and his colleagues at the Roslin Institute announced the successful cloning of a sheep, named Dolly, from the mammary glands of an adult female. The cloning of Dolly made it apparent to many that the techniques used to produce her could someday be used to clone human beings.^[17] This stirred a lot of controversy because of its ethical implications.

Agriculture[link]

Crop yield[link]

Using the techniques of modern biotechnology, one or two genes (Smartstax from Monsanto in collaboration with Dow AgroSciences will use 8, starting in 2010) may be transferred to a highly developed crop variety to impart a new character that would increase its yield.^[18] However, while increases in crop yield are the most obvious applications of modern biotechnology in agriculture, it is also the most difficult one. Current genetic engineering techniques work best for effects that are controlled by a single gene. Many of the genetic characteristics associated with yield (e.g., enhanced growth) are controlled by a large number of genes, each of which has a minimal effect on the overall yield.^[19] There is, therefore, much scientific work to be done in this area.

Reduced vulnerability of crops to environmental stresses[link]

Crops containing genes that will enable them to withstand biotic and abiotic stresses may be developed. For example, drought and excessively salty soil are two important limiting factors in crop productivity. Biotechnologists are studying plants that can cope with these extreme conditions in the hope of finding the genes that enable them to do so and eventually transferring these genes to the more desirable crops. One of the latest developments is the identification of a plant gene, At-DBF2, from Arabidopsis thaliana, a tiny weed that is often used for plant research because it is very easy to grow and its genetic code is well mapped out. When this gene was inserted into tomato and tobacco cells (see RNA interference), the cells were able to withstand environmental stresses like salt, drought, cold and heat, far more than ordinary cells. If these preliminary results prove successful in larger trials, then At-DBF2 genes can help in engineering crops that can better withstand harsh environments.^[20] Researchers have also created transgenic rice plants that are resistant to rice yellow mottle virus (RYMV). In Africa, this virus destroys majority of the rice crops and makes the surviving plants more susceptible to fungal infections.^[21]

Increased nutritional qualities[link]

Proteins in foods may be modified to increase their nutritional qualities. Proteins in legumes and cereals may be transformed to provide the amino acids needed by human beings for a balanced diet.^[19] A good example is the work of Professors Ingo Potrykus and Peter Beyer in creating Golden rice (discussed below).

Improved taste, texture or appearance of food[link]

Modern biotechnology can be used to slow down the process of spoilage so that fruit can ripen longer on the plant and then be transported to the consumer with a still reasonable shelf life. This alters the taste, texture and appearance of the fruit. More importantly, it could expand the market for farmers in developing countries due to the reduction in spoilage. However, there is sometimes a lack of understanding by researchers in developed countries about the actual needs of prospective beneficiaries in developing countries. For example, engineering soybeans to resist spoilage makes them less suitable for producing tempeh which is a significant source of protein that depends on fermentation. The use of modified soybeans results in a lumpy texture that is less palatable and less convenient when cooking.

The first genetically modified food product was a tomato which was transformed to delay its ripening.^[22] Researchers in Indonesia, Malaysia, Thailand, Philippines and Vietnam are currently working on delayed-ripening papaya in collaboration with the University of Nottingham and Zeneca.^[23]

Biotechnology in cheese production:^[24] enzymes produced by micro-organisms provide an alternative to animal rennet – a cheese coagulant – and an alternative supply for cheese makers. This also eliminates possible public concerns with animal-derived material, although there are currently no plans to develop synthetic milk, thus making this argument less compelling. Enzymes offer an animal-friendly alternative to animal rennet. While providing comparable quality, they are theoretically also less expensive.

About 85 million tons of wheat flour is used every year to bake bread.^[25] By adding an enzyme called maltogenic amylase to the flour, bread stays fresher longer. Assuming that 10–15% of bread is thrown away as stale, if it could be made to stay fresh another 5–7 days then perhaps 2 million tons of flour per year would be saved. Other enzymes can cause bread to expand to make a lighter loaf, or alter the loaf in a range of ways.

Reduced dependence on fertilizers, pesticides and other agrochemicals[link]

Most of the current commercial applications of modern biotechnology in agriculture are on reducing the dependence of farmers on agrochemicals. For example, Bacillus thuringiensis (Bt) is a soil bacterium that produces a protein with insecticidal qualities. Traditionally, a fermentation process has been used to produce an insecticidal spray from these bacteria. In this form, the Bt toxin occurs as an inactive protoxin, which requires digestion by an insect to be effective. There are several Bt toxins and each one is specific to certain target insects. Crop plants have now been engineered to contain and express the genes for Bt toxin, which they produce in its active form. When a susceptible insect ingests the transgenic crop cultivar expressing the Bt protein, it stops feeding and soon thereafter dies as a result of the Bt toxin binding to its gut wall. Bt corn is now commercially available in a number of countries to control corn borer (a lepidopteran insect), which is otherwise controlled by spraying (a more difficult process).

Crops have also been genetically engineered to acquire tolerance to broad-spectrum herbicide. The lack of herbicides with broad-spectrum activity and no crop injury was a consistent limitation in crop weed management. Multiple applications of numerous herbicides were routinely used to control a wide range of weed species detrimental to agronomic crops. Weed management tended to rely on preemergence—that is, herbicide applications were sprayed in response to expected weed infestations rather than in response to actual weeds present. Mechanical cultivation and hand weeding were often necessary to control weeds not controlled by herbicide applications. The introduction of herbicide-tolerant crops has the potential of reducing the number of herbicide active ingredients used for weed management, reducing the number of herbicide applications made during a season, and increasing yield due to improved weed management and less crop injury. Transgenic crops that express tolerance to glyphosate, glufosinate and bromoxynil have been developed. These herbicides can now be sprayed on transgenic crops without inflicting damage on the crops while killing nearby weeds.^[26]

From 1996 to 2001, herbicide tolerance was the most dominant trait introduced to commercially available transgenic crops, followed by insect resistance. In 2001, herbicide tolerance deployed in soybean, corn and cotton accounted for 77% of the 626,000 square kilometres planted to transgenic crops; Bt crops accounted for 15%; and "stacked genes" for herbicide tolerance and insect resistance used in both cotton and corn accounted for 8%.^[27]

Production of novel substances in crop plants[link]

Biotechnology is being applied for novel uses other than food. For example, oilseed can be modified to produce fatty acids for detergents, substitute fuels and petrochemicals. Potatoes, tomatoes, rice tobacco, lettuce, safflowers, and other plants have been genetically engineered to produce insulin and certain vaccines. If future clinical trials prove successful, the advantages of edible vaccines would be enormous, especially for developing countries. The transgenic plants may be grown locally and cheaply. Homegrown vaccines would also avoid logistical and economic problems posed by having to transport traditional preparations over long distances and keeping them cold while in transit. And since they are edible, they will not need syringes, which are not only an additional expense in the traditional vaccine preparations but also a source of infections if contaminated.^[28] In the case of insulin grown in transgenic plants, it is well-established that the gastrointestinal system breaks the protein down therefore this could not currently be administered as an edible protein. However, it might be produced at significantly lower cost than insulin produced in costly bioreactors. For example, Calgary, Canada-based SemBioSys Genetics, Inc. reports that its safflower-produced insulin will reduce unit costs by over 25% or more and approximates a reduction in the capital costs associated with building a commercial-scale insulin manufacturing facility of over $100 million, compared to traditional biomanufacturing facilities.^[29]

Animal biotechnology[link]

In animals, biotechnology techniques are being used to improve genetics and for pharmaceutical or industrial applications. Molecular biology techniques can help drive breeding programs by directing selection of superior animals. Animal cloning, through somatic cell nuclear transfer (SCNT), allows for genetic replication of selected animals. Genetic engineering, using recombinant DNA, alters the genetic makeup of the animal for selected purposes, including producing therapeutic proteins in cows and goats.^[30] There is a genetically altered salmon with an increased growth rate being considered for FDA approval.^[31]

Criticism[link]

There is another side to the agricultural biotechnology issue. It includes increased herbicide usage and resultant herbicide resistance, "super weeds," residues on and in food crops, genetic contamination of non-GM crops which hurt organic and conventional farmers, etc.^[32][33]

Biological engineering[link]

Biotechnological engineering or biological engineering is a branch of engineering that focuses on biotechnologies and biological science. It includes different disciplines such as biochemical engineering, biomedical engineering, bio-process engineering, biosystem engineering and so on. Because of the novelty of the field, bioengineer is still not clearly defined. However, in general it is an integrated approach of fundamental biological sciences and traditional engineering principles.

Biotechnologists are often employed to scale up bio processes from the laboratory scale to the manufacturing scale. Moreover, as with most engineers, they often deal with management, economic and legal issues. Since patents and regulation (e.g., U.S. Food and Drug Administration regulation in the U.S.) are very important issues for biotech enterprises, bioengineers are often required to have knowledge related to these issues.

The increasing number of biotech enterprises is likely to create a need for bioengineers in the years to come. Many universities throughout the world are now providing programs in bioengineering and biotechnology (as independent programs or specialty programs within more established engineering fields).

Bioremediation and biodegradation[link]

Biotechnology is being used to engineer and adapt organisms especially microorganisms in an effort to find sustainable ways to clean up contaminated environments. The elimination of a wide range of pollutants and wastes from the environment is an absolute requirement to promote a sustainable development of our society with low environmental impact. Biological processes play a major role in the removal of contaminants and biotechnology is taking advantage of the astonishing catabolic versatility of microorganisms to degrade/convert such compounds. New methodological breakthroughs in sequencing, genomics, proteomics, bioinformatics and imaging are producing vast amounts of information. In the field of Environmental Microbiology, genome-based global studies open a new era providing unprecedented in silico views of metabolic and regulatory networks, as well as clues to the evolution of degradation pathways and to the molecular adaptation strategies to changing environmental conditions. Functional genomic and metagenomic approaches are increasing our understanding of the relative importance of different pathways and regulatory networks to carbon flux in particular environments and for particular compounds and they will certainly accelerate the development of bioremediation technologies and biotransformation processes.^[34]

Marine environments are especially vulnerable since oil spills of coastal regions and the open sea are poorly containable and mitigation is difficult. In addition to pollution through human activities, millions of tons of petroleum enter the marine environment every year from natural seepages. Despite its toxicity, a considerable fraction of petroleum oil entering marine systems is eliminated by the hydrocarbon-degrading activities of microbial communities, in particular by a remarkable recently discovered group of specialists, the so-called hydrocarbonoclastic bacteria (HCCB).^[35]

Biotechnology regulations[link]

The National Institute of Health was the first federal agency to assume regulatory responsibility in the United States. The Recombinant DNA Advisory Committee of the NIH published guidelines for working with recombinant DNA and recombinant organisms in the laboratory. Nowadays, the agencies that are responsible for the biotechnology regulation are: US Department of Agriculture (USDA) that regulates plant pests and medical preparation from living organisms, Environmental Protection Agency (EPA) that regulates pesticides and herbicides, and the Food and Drug Administration (FDA) which ensures that the food and drug products are safe and effective ^[2]

Education[link]

In 1988, after prompting from the United States Congress, the National Institute of General Medical Sciences (National Institutes of Health) instituted a funding mechanism for biotechnology training. Universities nationwide compete for these funds to establish Biotechnology Training Programs (BTPs). Each successful application is generally funded for five years then must be competitively renewed. Graduate students in turn compete for acceptance into a BTP; if accepted then stipend, tuition and health insurance support is provided for two or three years during the course of their PhD thesis work. Nineteen institutions offer NIGMS supported BTPs.^[36] Biotechnology training is also offered at the undergraduate level and in community colleges.

See also[link]

Biotechnology portal

References and notes[link]

Further reading[link]

• Friedman, Yali (2008). Building Biotechnology: Starting, Managing, and Understanding Biotechnology Companies. Washington, DC: Logos Press. ISBN 978-0-9734676-3-5. http://www.buildingbiotechnology.com. 
• Oliver, Richard W.. The Coming Biotech Age. ISBN 0-07-135020-9. 
• Powell, Walter W.; White, Douglas R.; Koput, Kenneth W.; Owen-Smith, Jason (2005). "Network Dynamics and Field Evolution: The Growth of Interorganizational Collaboration in the Life Sciences". American Journal of Sociology 110 (4): 1132–1205. DOI:10.1086/421508.  Viviana Zelizer Best Paper in Economic Sociology Award (2005–2006), American Sociological Association.
• Zaid, A; H.G. Hughes, E. Porceddu, F. Nicholas (2001). Glossary of Biotechnology for Food and Agriculture — A Revised and Augmented Edition of the Glossary of Biotechnology and Genetic Engineering. Available in English, French, Spanish, Chinese, Arabic, Russian, Polish, Serbian, Vietnamese and Kazakh. Rome: FAO. ISBN 92-5-104683-2. http://www.fao.org/biotech/biotech-glossary/en/. 
• Agricultural Biotechnology: An Economic Perspective by the USDA Economic Research Service. A 1994 publication from the Agricultural Economic Report.

External links[link]

Wikibooks has a book on the topic of Genes, Technology and Policy

At Wikiversity you can learn more and teach others about Biotechnology at: The Department of Biotechnology

Look up biotechnology in Wiktionary, the free dictionary.

• The International Forum on Biotechnology
• Foundation for Biotechnology Awareness and Education,
• A report on Agricultural Biotechnology focusing on the impacts of "Green" Biotechnology with a special emphasis on economic aspects. fao.org.
• US Economic Benefits of Biotechnology to Business and Society NOAA Economics, economics.noaa.gov
• Database of the Safety and Benefits of Biotechnology – a database of peer-reviewed scientific papers and the safety and benefits of biotechnology.

Jay D. Keasling is a Professor of Chemical and Biomolecular Engineering and Bioengineering at the University of California, Berkeley.^[3][4] He is also Associate Laboratory Director for Biosciences at the Lawrence Berkeley National Laboratory, the Founding Head of the Synthetic Biology Department in the Physical Biosciences Division at Lawrence Berkeley National Laboratory, and chief executive officer of the Joint BioEnergy Institute.^[5] He is considered one of the foremost authorities in synthetic biology, especially in the field of metabolic engineering. Other, related research interests include systems biology and environmental biotechnology.

Keasling's current research^[6] involves the metabolic engineering of the Escherichia coli bacterium to produce biofuels and of the Saccharomyces cerevisiae yeast to produce the anti-malarial drug artemisinin.^[7][8] Although it is an effective, proven treatment for malaria, current methods of producing artemisinin (found naturally in the plant Artemisia annua) are considered too expensive to cost-effectively eliminate malaria from developing countries.^[9]

By producing the drug from a microbe, rather than harvesting it from a plantation, the Keasling Lab intends to lower the cost of artemisinin production from $2.40 per dose to $0.25 per dose.^[10]

In 2009, Keasling was awarded the first annual Biotech Humanitarian Award by BIO, the Biotechnology Industry Organization.^[11] In 2004, the Bill and Melinda Gates Foundation awarded a shared $42.5 million grant to the Keasling Lab, Amyris Biotechnologies, a company Keasling helped start,^[12] and the Institute for OneWorld Health to develop and distribute the low-cost malaria treatment.^[10] In 2006 Discover magazine awarded its first ever Scientist of the Year Award to Jay Keasling.^[13] Keasling is a member of the National Academy of Engineering.

Jay Keasling received his Bachelor's Degree at the University of Nebraska-Lincoln where he was a member of Delta Tau Delta International Fraternity. He received his Ph.D from the University of Michigan in 1991. He is originally from Harvard, Nebraska and is openly gay.^[14][15]

References[link]

External links[link]

• Jay Keasling on Twitter
• "Gates foundation to promote synthetic biology – CNET News". http://news.cnet.com/Gates-foundation-to-promote-synthetic-biology/2100-1008_3-5489245.html. Retrieved 2 July 2011. 
• "At Berkeley: Intelligently designed molecular evolution". http://www.eurekalert.org/pub_releases/2006-02/dbnl-abi022306.php. Retrieved 2 July 2011. 
• "11.15.2006 – Jay Keasling honored as Scientist of the Year". http://www.berkeley.edu/news/media/releases/2006/11/15_discovery.shtml. Retrieved 2 July 2011. 
• Jay Keasling talk given at PopTech conference

This article's lead section may not adequately summarize its contents. Please consider expanding the lead to provide an accessible overview of the article's key points. (May 2012)

Ray Kurzweil
Ray Kurzweil
Born	(1948-02-12) February 12, 1948 (age 64) Queens, New York, United States
Occupation	Author, entrepreneur and futurist
Spouse	Sonya R. Kurzweil
Children	Ethan, Amy

Raymond "Ray" Kurzweil (/ˈkɜrzwaɪl/ KURZ-wyl; born February 12, 1948) is an American author, inventor and futurist. Aside from futurology, he is involved in fields such as optical character recognition (OCR), text-to-speech synthesis, speech recognition technology, and electronic keyboard instruments. He is the author of several books on health, artificial intelligence (AI), transhumanism, the technological singularity, and futurism.

Life, inventions, and business career[link]

Early life[link]

Ray Kurzweil grew up in the New York City borough of Queens. He was born to secular Jewish parents who had escaped Austria just before the onset of World War II, and he was exposed via Unitarian Universalism to a diversity of religious faiths during his upbringing. His father was a musician and composer and his mother was a visual artist. His uncle, an engineer at Bell Labs, taught young Ray the basics of computer science.^[1] In his youth, he was an avid reader of science fiction literature. In 1963, at age fifteen, he wrote his first computer program.^[2] Later in high school he created a pattern-recognition software program that analyzed the works of classical composers, and then synthesized its own songs in similar styles. In 1965, he was invited to appear on the CBS television program I've Got a Secret, where he performed a piano piece that was composed by a computer he also had built.^[3] Later that year, he won first prize in the International Science Fair for the invention;^[4] he was also recognized by the Westinghouse Talent Search and was personally congratulated by President Lyndon B. Johnson during a White House ceremony.

Mid-life[link]

In 1968, during his sophomore year at MIT, Kurzweil started a company that used a computer program to match high school students with colleges. The program, called the Select College Consulting Program, was designed by him and compared thousands of different criteria about each college with questionnaire answers submitted by each student applicant. When he was 20, he sold the company to Harcourt, Brace & World for $100,000 (roughly $500,000 in 2006 dollars) plus royalties.^[5] He obtained a Bachelor of Science degree in Computer Science and Literature in 1970 from MIT.

In 1974, Kurzweil started the company Kurzweil Computer Products, Inc. and led development of the first omni-font optical character recognition system—a computer program capable of recognizing text written in any normal font. Before that time, scanners had only been able to read text written in a few fonts. He decided that the best application of this technology would be to create a reading machine, which would allow blind people to understand written text by having a computer read it to them aloud. However, this device required the invention of two enabling technologies—the CCD flatbed scanner and the text-to-speech synthesizer. Development of these technologies was completed at other institutions such as Bell Labs, and on January 13, 1976, the finished product was unveiled during a news conference headed by him and the leaders of the National Federation of the Blind. Called the Kurzweil Reading Machine, the device covered an entire tabletop. It gained him mainstream recognition: on the day of the machine's unveiling, Walter Cronkite used the machine to give his signature soundoff, "And that's the way it is, January 13, 1976." While listening to The Today Show, musician Stevie Wonder heard a demonstration of the device and purchased the first production version of the Kurzweil Reading Machine, beginning a lifelong friendship between himself and Kurzweil.

According to former Kurzweil Computer Products employees, the Kurzweil Reading Machine's designer was engineer Richard Brown, a KCP employee at the time^{[citation needed]}.

Kurzweil's next major business venture began in 1978, when Kurzweil Computer Products began selling a commercial version of the optical character recognition computer program. LexisNexis was one of the first customers, and bought the program to upload paper legal and news documents onto its nascent online databases.

Two years later, Kurzweil sold his company to Lernout & Hauspie. Following the bankruptcy of the latter, the system became a subsidiary of Xerox formerly known as Scansoft and now as Nuance Communications, and he functioned as a consultant for the former until 1995.

Kurzweil's next business venture was in the realm of electronic music technology. After a 1982 meeting with Stevie Wonder, in which the latter lamented the divide in capabilities and qualities between electronic synthesizers and traditional musical instruments, Kurzweil was inspired to create a new generation of music synthesizers capable of accurately duplicating the sounds of real instruments. Kurzweil Music Systems was founded in the same year, and in 1984, the Kurzweil K250 was unveiled. The machine was capable of imitating a number of instruments, and in tests musicians were unable to discern the difference between the Kurzweil K250 on piano mode from a normal grand piano.^[6] The recording and mixing abilities of the machine, coupled with its abilities to imitate different instruments made it possible for a single user to compose and play an entire orchestral piece.

Kurzweil Music Systems was sold to Korean musical instrument manufacturer Young Chang in 1990. As with Xerox, Kurzweil remained as a consultant for several years. Hyundai acquired Young Chang in 2006 and in January 2007 has appointed Raymond Kurzweil as Chief Strategy Officer of Kurzweil Music Systems.^[7]

Later life[link]

Concurrent with Kurzweil Music Systems, Kurzweil created the company Kurzweil Applied Intelligence (KAI) to develop computer speech recognition systems for commercial use. The first product, which debuted in 1987, was an early speech recognition program.

Kurzweil started Kurzweil Educational Systems in 1996 to develop new pattern-recognition-based computer technologies to help people with disabilities such as blindness, dyslexia and ADD in school. Products include the Kurzweil 1000 text-to-speech converter software program, which enables a computer to read electronic and scanned text aloud to blind or visually impaired users, and the Kurzweil 3000 program, which is a multifaceted electronic learning system that helps with reading, writing, and study skills.

Raymond Kurzweil at the Singularity Summit at Stanford in 2006

During the 1990s Kurzweil founded the Medical Learning Company.^[8] The company's products included an interactive computer education program for doctors and a computer-simulated patient. Around the same time, Kurzweil started KurzweilCyberArt.com—a website featuring computer programs to assist the creative art process. The site used to offer free downloads of a program called AARON—a visual art synthesizer developed by Harold Cohen—and of "Kurzweil's Cybernetic Poet", which automatically creates poetry. During this period he also started KurzweilAI.net, a website devoted towards showcasing news of scientific developments, publicizing the ideas of high-tech thinkers and critics alike, and promoting futurist-related discussion among the general population through the Mind-X forum.

In 1999, Kurzweil created a hedge fund called "FatKat" (Financial Accelerating Transactions from Kurzweil Adaptive Technologies), which began trading in 2006. He has stated that the ultimate aim is to improve the performance of FatKat's A.I. investment software program, enhancing its ability to recognize patterns in "currency fluctuations and stock-ownership trends."^[9] He predicted in his 1999 book, The Age of Spiritual Machines, that computers will one day prove superior to the best human financial minds at making profitable investment decisions. In 2001, Canadian rock band Our Lady Peace released an album, titled Spiritual Machines, based on Kurzweil's book. Kurzweil's voice was featured in the album, reading excerpts from his book.

In June 2005, Kurzweil introduced the "Kurzweil-National Federation of the Blind Reader" (K-NFB Reader)—a pocket-sized device consisting of a digital camera and computer unit. Like the Kurzweil Reading Machine of almost 30 years before, the K-NFB Reader is designed to aid blind people by reading written text aloud. The newer machine is portable and scans text through digital camera images, while the older machine is large and scans text through flatbed scanning.

Kurzweil made a movie called The Singularity Is Near: A True Story About the Future^[10] in 2010 based, in part, on his 2005 book The Singularity Is Near. Part fiction, part non-fiction, he interviews 20 big thinkers like Marvin Minsky, plus there is a B-line narrative story that illustrates some of the ideas, where a computer avatar (Ramona) saves the world from self-replicating microscopic robots.

In addition to his movie, an independent, feature-length documentary was made about Kurzweil, his life, and his ideas called Transcendent Man. Filmmakers Barry Ptolemy and Felicia Ptolemy followed Kurzweil, documenting his global speaking tour. Premiered in 2009 at the Tribeca Film Festival,^[10] Transcendent Man documents Kurzweil's quest to reveal mankind's ultimate destiny and explores many of the ideas found in his New York Times bestselling book, The Singularity Is Near, including his concept of exponential growth, radical life expansion, and how we will transcend our biology. The Ptolemys documented Kurzweil's stated goal of bringing back his late father using AI. The film also features critics who argue against Kurzweil's predictions.

In 2010, an independent documentary film called Plug & Pray premiered at the Seattle International Film Festival, in which Kurzweil and one of his major critics, the late Joseph Weizenbaum, argue about the benefits of eternal life.^[11]

Kurzweil frequently comments on the application of cell-size nanotechnology to the workings of the human brain and how this could be applied to building AI. While being interviewed for a February 2009 issue of Rolling Stone magazine, Kurzweil expressed a desire to construct a genetic copy of his late father, Fredric Kurzweil, from DNA within his grave site. This feat would be achieved by exhumation and extraction of DNA, constructing a clone of Fredric and retrieving memories and recollections—from Ray's mind—of his father.^[12]

Family[link]

Kurzweil is married with two children. His wife, Sonya, is a child psychologist while his son works as a venture capitalist and his daughter as a choreographer.^[13]

Books[link]

Kurzweil's first book, The Age of Intelligent Machines, was published in 1990. The nonfiction work discusses the history of computer AI and also makes forecasts regarding future developments. Other experts in the field of AI contribute heavily to the work in the form of essays. The Association of American Publishers' awarded it the status of Most Outstanding Computer Science Book of 1990.^[14]

Next, Kurzweil published a book on nutrition in 1993 called The 10% Solution for a Healthy Life. The book's main idea is that high levels of fat intake are the cause of many health disorders common in the U.S., and thus that cutting fat consumption down to 10% of the total calories consumed would be optimal for most people.

In 1998, Kurzweil published The Age of Spiritual Machines, which focuses heavily on further elucidating his theories regarding the future of technology, which themselves stem from his analysis of long-term trends in biological and technological evolution. Much focus goes into examining the likely course of AI development, along with the future of computer architecture.

Kurzweil's next book published in 2004, returned to the subject of human health and nutrition. Fantastic Voyage: Live Long Enough to Live Forever was co-authored by Kurzweil and Terry Grossman, a medical doctor and specialist in alternative medicine.

The Singularity Is Near was published in 2005. The book was made into a movie starring Pauley Perrette (NCIS).^[15]

In February 2007, Ptolemaic Productions acquired the rights to The Singularity is Near, The Age of Spiritual Machines and Fantastic Voyage including the rights to Kurzweil's life and ideas for the film Transcendent Man. The feature length documentary was directed by Barry Ptolemy.

Transcend: Nine Steps to Living Well Forever,^[16] a follow-up to Fantastic Voyage, was released on April 28, 2009.

Kurzweil's newest book, How to Create a Mind: The Secret of Human Thought Revealed, is scheduled for release on October 2, 2012. ^[17]

Recognition and awards[link]

Kurzweil was referred to by Forbes as "the ultimate thinking machine."^[18]

Kurzweil has received many awards and honors, including:

• First place in the 1965 International Science Fair^[4] for inventing the classical music synthesizing computer.
• The 1978 Grace Murray Hopper Award from the Association for Computing Machinery. The award is given annually to one "outstanding young computer professional" and is accompanied by a $35,000 prize.^[19] Kurzweil won it for his invention of the Kurzweil Reading Machine.^[20]
• The 1990 "Engineer of the Year" award from Design News.^[21]
• The 1994 Dickson Prize in Science. One is awarded every year by Carnegie Mellon University to individuals who have "notably advanced the field of science." Both a medal and a $50,000 prize are presented to winners.^[22]
• The 1998 "Inventor of the Year" award from the Massachusetts Institute of Technology.^[23]
• The 1999 National Medal of Technology.^[24] This is the highest award the President of the United States can bestow upon individuals and groups for pioneering new technologies, and the President dispenses the award at his discretion.^[25] Bill Clinton presented Kurzweil with the National Medal of Technology during a White House ceremony in recognition of Kurzweil's development of computer-based technologies to help the disabled.
• The 2000 Telluride Tech Festival Award of Technology.^[26] Two other individuals also received the same honor that year. The award is presented yearly to people who "exemplify the life, times and standard of contribution of Tesla, Westinghouse and Nunn."
• The 2001 Lemelson-MIT Prize for a lifetime of developing technologies to help the disabled and to enrich the arts.^[27] Only one is meted out each year to highly successful, mid-career inventors. A $500,000 award accompanies the prize.^[28]
• Kurzweil was inducted into the National Inventors Hall of Fame in 2002 for inventing the Kurzweil Reading Machine.^[29] The organization "honors the women and men responsible for the great technological advances that make human, social and economic progress possible."^[30] Fifteen other people were inducted into the Hall of Fame the same year.^[31]
• The Arthur C. Clarke Lifetime Achievement Award on April 20, 2009 for lifetime achievement as an inventor and futurist in computer-based technologies.^[32]
• Kurzweil has received seventeen honorary doctorates between 1982 and 2010.^{[citation needed]}
• In 2011, Kurzweil was named a Senior Fellow of the Design Futures Council.^[33]

Involvement with futurism and transhumanism[link]

Kurzweil is generally recognized as a public advocate for the futurist and transhumanist movements, due to his stances on life extension technologies, his efforts to forecast future advances in technology, and his interest in the concept of the technological singularity. At the same time, he has attracted significant criticism from scientists and thinkers.

Kurzweil's central argument is derived from the predictions of Moore's Law that the rate of innovation of computer technology is increasing not linearly but rather exponentially. According to Kurzweil's argument, since growth in so many fields of science and technology depends upon computing power, these improvements translate into exponentially more frequent advances in non-computer sciences like nanotechnology, biotechnology, and materials science. Kurzweil refers to this concept as the "Law of Accelerating Returns", and has asserted that this is supported by a number of metrics.

Kurzweil has forecast a number of specific technological advances with specific dates in his books, stating that before 2050 medical advances will allow people to radically extend their lifespans while preserving quality of life through the use of nanobots,^[3][34] that a computer will pass the Turing test by 2029, that the first strong artificial intelligence will be a computer simulation of a human brain generated by nanorobotic brain scanning, sentient artificial intelligences will exhibit moral thinking and respect humans, and that the line between humans and machines will blur as machines attain human-level intelligence and humans start incorporating more technology.

Kurzweil's application of his law to forecasting innovations have been disputed by other scientists and writers.^[35]

Kurzweil's standing as a futurist and Transhumanist has led to his involvement in several Singularity-themed organizations. In December 2004, Kurzweil joined the advisory board of the Singularity Institute for Artificial Intelligence.^[36] In October 2005, Kurzweil joined the scientific advisory board of the Lifeboat Foundation.^[37] On May 13, 2006, Kurzweil was the first speaker at the Stanford University Singularity Summit.^[38]

In February 2009, Kurzweil, in collaboration with Google and the NASA Ames Research Center, announced the creation of the Singularity University training center for corporate executives and government officials. The University's self-described mission is to "assemble, educate and inspire a cadre of leaders who strive to understand and facilitate the development of exponentially advancing technologies and apply, focus and guide these tools to address humanity’s grand challenges".^[39] Using Vernor Vinge's Singularity concept as a foundation, the University offered its first nine-week graduate program to forty students in June, 2009.

Stance on nanotechnology[link]

Kurzweil is on the Army Science Advisory Board, has testified before Congress on the subject of nanotechnology, and has advocated that nanotechnology could solve significant global problems such as poverty, disease, and climate change, viz. "Nanotech Could Give Global Warming a Big Chill ".^[40] In media appearances, Kurzweil has stressed the extreme potential dangers of nanotechnology,^[3] but argues that in practice, progress cannot be stopped, and any attempt to do so will retard the progress of defensive and beneficial technologies more than the malevolent ones, increasing the danger. He suggests that the proper place of regulation is to make sure progress proceeds safely and quickly.

[edit] The Law of Accelerating Returns

In his 1999 book The Age of Spiritual Machines Kurzweil proposed "The Law of Accelerating Returns", according to which the rate of change in a wide variety of evolutionary systems (including the growth of technologies) tends to increase exponentially.^[41] He gave further focus to this issue in a 2001 essay entitled "The Law of Accelerating Returns", which proposed an extension of Moore's law to a wide variety of technologies, and used this to argue in favor of Vernor Vinge's concept of a technological singularity.^[42]

Predictions[link]

[edit] The Age of Intelligent Machines

Kurzweil's first book, The Age of Intelligent Machines, presented his ideas about the future. It was written from 1986 to 1989 and published in 1990. Building on Ithiel de Sola Pool's "Technologies of Freedom" (1983), Kurzweil claims to have forecast the demise of the Soviet Union due to new technologies such as cellular phones and fax machines disempowering authoritarian governments by removing state control over the flow of information. In the book Kurzweil also extrapolated preexisting trends in the improvement of computer chess software performance to predict correctly that computers would beat the best human players by 1998, and most likely in that year. In fact, the event occurred in May 1997 when chess World Champion Garry Kasparov was defeated by IBM's Deep Blue computer in a well-publicized chess tournament. Perhaps most significantly, Kurzweil foresaw the explosive growth in worldwide Internet use that began in the 1990s. At the time of the publication of The Age of Intelligent Machines, there were only 2.6 million Internet users in the world,^[43] and the medium was unreliable, difficult to use, and deficient in content. He also stated that the Internet would explode not only in the number of users but in content as well, eventually granting users access "to international networks of libraries, data bases, and information services". Additionally, Kurzweil claims to have correctly foreseen that the preferred mode of Internet access would inevitably be through wireless systems, and he was also correct to estimate that the latter would become practical for widespread use in the early 21st century.

Kurzweil also claims to have accurately forecast that, by the end of the 1990s, many documents would exist solely in computers and on the Internet, and that they would commonly be embedded with sounds, animations, and videos that would inhibit their transfer to paper format. Moreover, he claims to have foreseen that cellular phones would grow in popularity while shrinking in size for the foreseeable future.

[edit] The Age of Spiritual Machines

In 1999, Kurzweil published a second book titled The Age of Spiritual Machines, which goes into more depth explaining his futurist ideas. The third and final section of the book is devoted to elucidating the specific course of technological advancements Kurzweil predicts the world will experience over the next century.

[edit] The Singularity is Near

While this book focuses on the future of technology and the human race as did The Age of Intelligent Machines and The Age of Spiritual Machines, Kurzweil makes very few concrete, short-term predictions in The Singularity Is Near, though longer-term visions are present in abundance. He recently discussed the singularity with Vice Magazine.^[44]

Solar Power and Grand Challenges of the 21st Century[link]

In 2008, Ray Kurzweil said in an expert panel in the National Academy of Engineering that solar power will scale up to produce all the energy needs of Earth's people in 20 years.^[45]

Work on nutrition, health, and lifestyle[link]

Kurzweil admits that he cared little for his health until age 35, when he was diagnosed with a glucose intolerance, an early form of type II diabetes (a major risk factor for heart disease). Kurzweil then found a doctor that shares his non-conventional beliefs to develop an extreme regimen involving hundreds of pills, chemical i.v. treatments, red wine and various other methods to attempt to live longer.

Kurzweil ingests "250 supplements, eight to 10 glasses of alkaline water and 10 cups of green tea" every day and drinks several glasses of red wine a week in an effort to "reprogram" his biochemistry.^[46] Lately, he has cut down the number of supplement pills to 150.^[47]

Kurzweil joined the Alcor Life Extension Foundation, a cryonics company. In the event of his death, Kurzweil's body will be chemically preserved, frozen in liquid nitrogen, and stored at an Alcor facility in the hope that future medical technology will be able to revive him.^{[citation needed]}

Kurzweil has authored three books on the subjects of nutrition, health and immortality: The 10% Solution for a Healthy Life, Fantastic Voyage: Live Long Enough to Live Forever and TRANSCEND: Nine Steps to Living Well Forever.^[48] In all, he recommends that other people emulate his health practices to the best of their abilities.

Kurzweil and his current "anti-aging" doctor, Terry Grossman, MD., now have two websites promoting their first^[49] and second book.^[50]

Stance on religion[link]

This section has multiple issues. Please help improve it or discuss these issues on the talk page. It needs additional citations for verification. Tagged since January 2012. It may contain original research. Tagged since June 2011.

Though Kurzweil's parents were Jewish, they raised him as a Unitarian Universalist and exposed him to many different faiths during his youth. Kurzweil presented sermons at the First Unitarian Universalist Church of San Diego in January 2000 upon publication of The Age of Spiritual Machines. He gave a 2007 keynote speech to the United Church of Christ in Hartford, Connecticut, alongside Barack Obama, who was then a Presidential candidate. In The Singularity is Near he expresses his belief in a need for a new religion based on the principle of mutual respect between sentient life forms, and on the principle of respecting knowledge. This religion would not have a leader, instead being purely personal to adherents.

The documentary Transcendent Man (2009) reveals some aspects of Kurzweil's spiritual beliefs. He discusses how he was raised, saying that recent exciting events, whether they were scientific discoveries, inventions, or something sociological or something else, were often topics that came up at the dinner table. He says that human knowledge was highly respected in his family, and particularly the ability for humans to overcome challenges. He says this respect for human knowledge was personalized even, and was part of the religion, if you will, of his family.

Parts of the film discuss the vast level of superiority computers already have versus humans at most basic tasks, such as math. Some say that the artificial intelligences we may build in the future will be gods, or god-like. Kurzweil seems to indicate however that the AIs paving the future will actually be us, man merged with machine, rather than (or perhaps in addition to) separate robot entities apart from ourselves.

At the end of the film, Kurzweil talks more about his ideas about the future and particularly about this unification of all people on Earth, followed by an expansion of our civilization and consciousness outward into the universe (after the singularity takes place), "waking up" things in its path (bringing consciousness).

His abridged way of saying it is that "it will be the universe waking up." After this, the loud, triumphant music that had been accompanying the scene cuts out, and the camera focuses back on Kurzweil, who then finishes the film by saying:

"So you might ask 'Does god exist?' Well, I would say not yet."

Criticism[link]

This article's Criticism or Controversy section may compromise the article's neutral point of view of the subject. Please integrate the section's contents into the article as a whole, or rewrite the material. (April 2010)

Kurzweil's ideas have generated much criticism within the scientific community and in the media. There are philosophical arguments over whether a machine can "think" (see Philosophy of artificial intelligence). Mitch Kapor, the founder of Lotus Development Corporation, has called the notion of a technological singularity "intelligent design for the IQ 140 people...This proposition that we're heading to this point at which everything is going to be just unimaginably different—it's fundamentally, in my view, driven by a religious impulse. And all of the frantic arm-waving can't obscure that fact for me."^[51]

VR pioneer Jaron Lanier has been one of the strongest critics of Kurzweil’s ideas, describing them as “cybernetic totalism”, and has outlined his views on the culture surrounding Kurzweil’s predictions in an essay for Edge.org entitled One Half of a Manifesto.^[52]

Pulitzer Prize winner Douglas Hofstadter, author of Gödel, Escher, Bach, has said of Kurzweil's and Hans Moravec's books: "It’s as if you took a lot of very good food and some dog excrement and blended it all up so that you can't possibly figure out what's good or bad. It's an intimate mixture of rubbish and good ideas, and it's very hard to disentangle the two, because these are smart people; they're not stupid."^[53]

Although the idea of a technological singularity is a popular concept in science fiction, some authors such as Neal Stephenson^[54] and Bruce Sterling have voiced scepticism about its real-world plausibility. Sterling expressed his views on the singularity scenario in a talk at the Long Now Foundation entitled The Singularity: Your Future as a Black Hole.^[55][56] Other prominent AI thinkers and computer scientists such as Daniel Dennett,^[57] Rodney Brooks,^[58] and David Gelernter^[59] have also criticized Kurzweil’s projections.

Bill Joy, cofounder of Sun Microsystems, agrees with Kurzweil's timeline of future progress, but thinks that technologies such as AI, nanotechnology and advanced biotechnology will create a dystopian world.^[60]

Daniel Lyons, writing in Newsweek, criticized Kurzweil for some of his predictions which turned out to be wrong; such as the economy continuing to boom from the 1998 dot-com through 2009, a US company having a market capitalization of more than $1 trillion, a supercomputer achieving 20 petaflops, speech recognition being in widespread use and cars that would drive themselves using sensors installed in highways; all by 2009.^[61] To the charge that a 20 petaflop supercomputer was not produced in the time he predicted, Kurzweil responded that he considers Google a giant supercomputer, and that it is indeed capable of 20 petaflops.^[61] In 2009 however IBM announced the commencement of its development of the IBM Sequoia for the Department of Energy's National Nuclear Security Administrations, which is capable of 20+ petaflops and is expected to be delivered in 2011,^{[non-primary source needed]} two years after Kurzeil's prediction.^[62]

Biologist P. Z. Myers has criticized Kurzweil's predictions as being based on "New Age spiritualism" rather than science and says that Kurzweil does not understand basic biology.^[63][64]

See also[link]

References[link]